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5-Androstene-3b,17b-diol
(5-AED) stimulates recovery
of hematopoiesis after expo-
sure to radiation. To eluci-
date its cellular targets, the
effects of 5-AED alone and
in combination with
granulocyte-colony stimu-
lating factor and thrombo-
poietin (TPO) on immature
hematopoietic progenitor
cells were evaluated
following total body irradia-
tion. 5-AED potently coun-
teracts the hematopoietic
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Open access undPurpose: 5-Androstene-3b,17b-diol (5-AED) stimulates recovery of hematopoiesis after expo-
sure to radiation. To elucidate its cellular targets, the effects of 5-AED alone and in combination
with (pegylated) granulocyte colony-stimulating factor and thrombopoietin (TPO) on immature
hematopoietic progenitor cells were evaluated following total body irradiation.
Methods and Materials: BALB/c mice were exposed to radiation delivered as a single or as
a fractionated dose, and recovery of bone marrow progenitors and peripheral blood parameters
was assessed.
Results: BALB/c mice treated with 5-AED displayed accelerated multilineage blood cell
recovery and elevated bone marrow (BM) cellularity and numbers of progenitor cells. The
spleen colony-forming unit (CFU-S) assay, representing the life-saving short-term repopulating
cells in BM of irradiated donor mice revealed that combined treatment with 5-AED plus TPO
resulted in a 20.1-fold increase in CFU-S relative to that of placebo controls, and a 3.7 and 3.1-
fold increase in comparison to 5-AED and TPO, whereas no effect was seen of Peg-G-CSF with
or without 5-AED. Contrary to TPO, 5-AED also stimulated reconstitution of the more imma-
ture marrow repopulating (MRA) cells.
Conclusions: 5-AED potently counteracts the hematopoietic effects of radiation-induced mye-
losuppression and promotes multilineage reconstitution by stimulating immature bone marrow
cells in a pattern distinct from, but synergistic with TPO.
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immature bone marrow cells
in a pattern distinct from but
synergistic with TPO.Introduction
Many hematopoietic growth factors have been tested for radia-
tion mitigation potential after myelosuppressive therapy.
The most potent among these are interleukin-11 (IL-11) (1),
granulocyte-colony stimulating factor (G-CSF) (2, 3),
granulocyte/macrophage-colony stimulating factor (GM-CSF)
(2, 3), and, in particular, thrombopoietin (TPO), which was
shown in preclinical studies to be the most effective radiation
mitigation drug when used as a single agent (3, 4). Both
GM-CSF and G-CSF are registered for treatment-related neu-
tropenia and display modest effects on survival and neutrophil
recovery when administered within 24 h after total body irradi-
ation (TBI). However, these agents only alleviate recovery in
a sublethal setting (3, 5) and are ineffective at a lethal dose
(6, 7). TPO stimulates recovery of all bone marrow (BM) and
spleen progenitor cells, affecting the complete hematopoietic
compartment and promoting recovery of life-saving short-term
multilineage spleen-repopulating cells (spleen colony-forming
unit [CFU-S]) in mice, but at the transient expense of the
more immature marrow repopulating cells (MRA) (4).
5-AED, a naturally occurring adrenocortical steroid hormone,
displays immune modulation (8) and myelopoiesis stimulation
properties in irradiated mice (9, 10) and monkeys (11, 12),
resulting in resistance to infections (13) and increased survival
(9). The cellular mechanisms of 5-AED may be partly mediated
by G-CSF (14) and IL-6 (15). We hypothesized that combination
treatment of 5-AED with pegylated G-CSF (Peg-G-CSF) and
TPO might result in an additive effect on hematopoietic cell
recovery. We studied the effects of 5-AED with and without Peg-
G-CSF and TPO on immature repopulating and progenitor cell
subsets in myelosuppressed mice by enumerating early stem cells
and their immediate progeny to gain insight into the cellular
targets from which the radiation mitigation effects of 5-AED
originate.
Methods and Materials
Animals
BALB/c mice, 8-12 weeks of age, were bred at the Experimental
Animal Facility of the Erasmus Medical Center (Rotterdam, The
Netherlands) and maintained under specific pathogen-free condi-
tions. An independent ethical committee approved housing,
experiments, and all other conditions in accordance with legal
regulations in The Netherlands.
Experimental design
Mice were subjected to TBI at day 0, using two opposing
137Cs-labled sources (Gammacell 40; Atomic Energy of Canada,
Ottawa, Canada) at dose rates between 0.92 and 0.94 Gy/min.Mice received 5.5 or 6.0 Gy TBI delivered as a single dose or 9 Gy
TBI delivered as 3 fractionated doses of 3 Gy each to measure
peripheral blood (PB) reconstitution. At days 10, 14, 17, and 21,
an experimental group of 3 mice was sacrificed (See Supplemental
Table E1).
Test drugs
5-AED (25-200 mg/kg/day), prepared as a solution of 100 mg/ml
in 7.4 mM sodium phosphate buffer, pH 6.0, containing 0.5%
polysorbate 80, 0.02% benzalkonium chloride, and 4.0%-4.8%
mannitol and its vehicle (12) was provided by Harbor BioSciences
Inc, San Diego, CA and administered intramuscularly (IM).
Recombinant murine TPO (Genentech Inc, South San Francisco,
CA) was diluted in phosphate-buffered saline (PBS) supplemented
with 0.01% Tween 20 and administered intraperitoneally (IP) at
9-28 mg/kg. These doses were effective in a similar model for
myelosuppression (4). Pegylated recombinant human G-CSF
(Amgen Europe, Breda, The Netherlands) was used at 400 mg/kg
and administered IP. All drugs were administered 2 h after TBI.
Hematologic examinations
After being anesthetized with iosoflurane, mice were bled by
retro-orbital puncture and killed by cervical dislocation. Complete
blood cell counts were measured using a Vet ABC hematology
analyzer (Scil Animal Care Co GmbH, Germany).
Measurements of surface antigens
BM, spleen, and PB cells of each mouse individually were
collected for flow cytometric analysis (9). Monoclonal antibodies
against murine CD4, CD8, CD11b, and B220 were purchased
from BD Biosciences, San Jose, CA. Samples were measured
using a FACSCalibur unit, and 10,000 events were analyzed using
Cellquest (BD Biosciences, San Jose, CA).
In vitro clonogenic progenitor assays
On days 10, 14, 17, and 21 after TBI, mice were killed, and femurs
and spleens were collected. Murine BM cells, 5 104, or 5% of the
total cell content of the spleen were plated in serum-free methyl-
cellulose culture medium, as described previously (4). Granulocyte/
macrophage colony formation (CFU-GM) was stimulated with
10 ng/mL murine interleukin-3 (mIL-3), 100 ng/mL murine stem
cell factor (mSCF), and 20 ng/mL GM-CSF; burst-forming
erythroid (BFU-E) growth with 100 ng/mL mSCF and 4 U/mL
human erythropoietin (hEPO; Behringwerke, Marburg, Germany);
and colony-forming unit erythroid (CFU-E) with hEPO. Megakar-
yocyte progenitor cells (CFU-Meg) were stimulated in 0.275% agar
cultures with 100 ng/mL SCF, 10 ng/mL mIL-3, and 10 ng/mL
murine TPO (mTPO) (Genentech Inc San Francisco, CA).
Fig. 1. Regeneration patterns of peripheral blood cells after
a single myelosuppressive dose of TBI Regeneration pattern of
white blood cells (A), platelets (B), and red blood cells (C) in mice
subjected to 5.5-6.0 Gy TBI and treated with a single dose of 40
mg/kg 5-AED (diamonds), placebo (crosses), and radiation
controls (triangles), data are the average  SD of 5 different
experiments, nZ3 mice per data point per experiment. Signifi-
cantly different from time matched placebo controls: *P<.05;
**P<.01; ***P<.001.
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To amplify 5-AED response on residual hematopoietic stem cells,
donor mice were subjected to 3  2 Gy with 24-h intervals as
previously described (4). Two hours after each fraction, mice were
injected with vehicle or 40 mg/kg/day 5-AED IM for 3 days or
28 mg/kg mTPO, or 400 mg/kg Peg-G-CSF IP after the first frac-
tion only. In addition, radiation controls did not receive injections.
At 24 h after the last irradiation, mice were sacrificed, and one-
tenth to one-half of the cell content of 1 femur was injected
intravenously into lethally (8 Gy) irradiated BALB/c mice to
perform the spleen colony assay as described by Till and
McCulloch (16). At day 12, mice were sacrificed and macro-
scopically visible spleen colonies, designated CFU-S-12, were
counted (see Supplementary Table E1, lower panel).
Marrow repopulating ability
BM from 3  2-Gy-irradiated control or 5-AED-treated mice was
collected 24 h after the last fraction of TBI and injected into
lethally (8-Gy) irradiated recipients. After 13 days, BM of
recipient mice was assayed for the presence of CFU. MRA was
expressed as the number of CFU per recipient femur. Control mice
were injected with the standard number of 105 BM cells (see
Supplementary Table E1, lower panel).
Statistics
Standard deviations of the mean were calculated on the assump-
tion of a normal distribution. The standard error of CFU-S-12 was
calculated on the assumption that crude colony counts are Poisson
distributed. Differences in repopulating abilities between each
group were evaluated using 1-way ANOVA. Colony assays were
performed in duplicate for individual mice. Results of colony
assays are expressed as the means  SD per femur or spleen for at
least 3 mice per group.
Results
Efficacy of 5-AED after exposure to a single
myelosuppressive dose of radiation
5-AED stimulates multilineage hematopoiesis
Exposure of BALB/c mice to 5.5 or 6 Gy TBI induced BM
suppression and pancytopenia. Treatment with 40mg/kg 5-AED IM
resulted in accelerated multilineage recovery (Fig. 1). Levels of
white blood cells (P<.001), platelets (P<.01), and red blood cells
(P<.05) were significantly higher in the 5-AED-treated group at
days 14, 17, and 21 postirradiation. Recovery of PBwas preceded by
accelerated recovery of BM cellularity (Fig. 2) with 7.8 2.8 106
cells in the 5-AED-treated group vs 3.3  2.0  106 cells in the
placebo control group as early as 10 days after irradiation (P<.001)
and accompanied by accelerated normalization of spleen cellularity
at day 14 in the 5-AED group on average 97.5  76.4  106 cells/
spleen in comparison to the placebo-treated group with 14.7  9.9
 106 cells/spleen (P<.01). The robust multilineage reconstitution
can be explained by the prominent effect of 5-AEDon reconstitution
of BM progenitor cells along the neutrophil, erythroid and
megakaryocytic lineages (see Supplementary Fig. E1). FemoralCFU-GM (P<.001), BFU-E (P<.01), CFU-E (P<.001), and
CFU-Meg (P<.05) reached consistently higher numbers from day
10 after irradiation in the 5-AED-treated group. Fluorescence-
activated cell sorting analysis of PB, BM, and spleen cells
revealed a consistent 2- to 3-fold increase in absolute numbers of
CD11b-positive cells in 5-AED-treated mice in comparison to
Fig. 2. Regeneration of bone marrow (BM) and spleen cells
after a single myelosuppressive dose of TBI Regeneration of total
nucleated cells (TNC) in BM per femur (A) and spleen (B) in mice
subjected to 5.5-6.0 Gy TBI and treated with a single dose of 40
mg/kg 5-AED (diamonds), placebo (crosses), and radiation
controls (triangles). Data are presented as the average  SD of 5
different experiments, nZ3 mice per data point per experiment.
Significantly different from time matched placebo controls
**P<.01.
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lymphocytes.
Effect of combined treatment of 5-AED and Peg-G-CSF or
TPO
Exposure of BALB/c mice to 5.5 or 6.0 Gy TBI and treatment with
40 mg/kg 5-AED, 10 mg Peg-G-CSF, 0.225 mg TPO, or combina-
tions thereof resulted in significantly enhanced numbers of white
blood cells, platelets, BM, and spleen cellularity (P<.01) at day 14
after irradiation in comparison to placebo mice (see Supplementary
Table E2). Combined treatment of 5-AED with Peg-G-CSF or TPO
dampened the lineage-specific response of either drug in favor of
a more general response (see Supplementary Table E3).
Efficacy of 5-AED after fractionated irradiation
Effects of 5-AED or Peg-G-CSF on hematopoietic
recovery
To amplify the 5-AED response, mice were subjected to 3  2 Gy
TBI (4). This regimen induces a more profound pancytopenia thana single mid-lethal dose of TBI. Mice treated with 5-AED or
Peg-G-CSF showed higher counts of white blood cells (P<.05)
and platelets (P<.0001) at day 17 after TBI in comparison to
placebo controls (Fig. 3). BM and spleen cellularity was signifi-
cantly increased (Fig. 4) at day 17, with 6.9  1.1  106 BM cells
(P<.01) in the 5-AED-treated group and 12.9  2.0  106 BM
cells (P<.001) in the Peg-G-CSF-treated group in comparison
with 2.9  .9  106 for placebo controls, paralleling
138.0  15.1  106 cells/spleen (P<.001) in the 5-AED group and
92.4  6.2  106 cells/spleen (P<.01) in the Peg-G-CSF-treated
group relative to 35.9  22.8  106 spleen cells in placebo mice.
Effect of 5-AED on MRA
Eight-Gy-irradiated mice transplanted with 5-AED-treated BM
cells showed 100% survival vs 80% in the radiation control group.
The number of secondary GM-CFU present in the BM of lethally
irradiated recipients was increased for the 5-AED group
in comparison to radiation controls, that is, 104 (10 mice) vs
1.4  103 colonies (8 mice), respectively. Spleen GM-CFU were
increased (P<.001) for the 5-AED-treated group in comparison to
radiation controls (Fig. 5).
Effect of 5-AED on short-term repopulating stem cells
(CFU-S-12)
Fig. 6 demonstrates that in comparison to mice transplanted with
untreated irradiated BM cells, administration of 5-AED to irra-
diated bone marrow donors (see Materials and Methods) resulted
in a 5.4-fold increase of CFU-S-12 in recipient mice (P<105).
Treatment with TPO resulted in a 6.5-fold increase in CFU-S-12
(P<105). 5-AED synergized with TPO, resulting in a 20.1-fold
increase in CFU-S-12 (P<1010) but not with Peg-G-CSF.
Differences among mice treated with TPO plus 5-AED and TPO
or 5-AED alone were highly significant, at P<107 and <1010,
respectively.
Discussion
Immune response modulation and protection from lethal microbial
challenge, attributes previously ascribed to dehydroepiandroster-
one (DHEA) (17), have now been shown to be mediated by
5-AED, a metabolite of DHEA (13, 17, 18). Protective effects of
5-AED are more pronounced under conditions of increased
susceptibility to infections, increased age (18), or after myelo-
suppression (8, 9). 5-AED ameliorates neutropenia and thrombo-
cytopenia in irradiated mice (9, 14) and nonhuman primates
(11, 12) resulting in increased survival and a radiation dose
reduction factor of 1.3 (9).
The present study demonstrates that 40 mg/kg 5-AED after
a single dose of 6 Gy TBI or 25 mg/kg/d 5-AED after 3  3 Gy
fractionated TBI adequately counteracts radiation-induced
pancytopenia and promotes multilineage hematopoietic reconsti-
tution and an increase of BM cellularity and elevated numbers of
hematopoietic progenitor cells at 14 days postirradiation (6 Gy
TBI) or at 17 days postirradiation (3  3 Gy TBI).
Effects of G-CSF in humans are lineage-restricted and result in
expansion of surviving neutrophil precursors rather than in
increased survival of immature cells (19, 20), whereas in mice,
treatment may result in enhanced multilineage recovery.
Maximum stimulation of hematopoietic progenitor cells by Peg-
G-CSF may have concealed possible synergism of 5-AED and
Peg-G-CSF. Saturation of G-CSF-receptors by Peg-G-CSF may
Fig. 3. Regeneration pattern of peripheral blood cells after
fractionated TBI Regeneration pattern of white blood cells (A),
platelets (B), and red blood cells (C) in mice irradiated with 3  3
Gy TBI and treated with 25 mg/kg/d 5-AED (diamonds) 2 h after
each fraction, or placebo (triangles) IM or 400 mg/kg Peg-G-CSF
(crosses) IP after the first irradiation only. Data are the average 
SD of 2 separate experiments, nZ3 mice per data point per
experiment. Significantly different from time matched placebo
controls *P<.05; **P<.01; ***P<.001.
Fig. 4. Regeneration of bone marrow and spleen cells after
fractionated TBI Regeneration of BM (A) and spleen (B) total
nucleated cells (TNC) in mice subjected to 3  3 Gy TBI and
treated with 25 mg/kg/d 5-AED (diamonds), Peg-G-CSF (crosses),
and placebo controls (triangles). Data are the average  SE, nZ3
per group. Significantly different from time matched vehicle
treated controls *P<.05; **P<.01; ***P<.001.
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additive effects. Combined treatment with 5-AED and Peg-G-CSF
resulted in a shift from a lineage-specific to a more generally
enhanced recovery. A possible working mechanism of 5-AED
might involve modulation of G-CSF levels. Indeed, accelerated
hematopoietic recovery and increased survival after treatment of
irradiated mice with 5-AED was accompanied by increased levels
of circulating G-CSF (14). NFkB is essential in the regulation ofmany hematopoietic growth factors and data demonstrating that
5-AED promotes survival of irradiated hematopoietic progenitor
cells by NFkB induced G-CSF secretion in vitro (15) would be
consistent with this mechanism.
A single injection of TPO after TBI was shown to give mul-
tilineage recovery of PB cells and BM progenitors (4). Here, we
used a suboptimal dose of TPO to uncover additive or synergistic
effects of combined 5-AED and TPO treatment. As plasma
erythropoietin levels are reciprocally related to levels of peripheral
red blood cells, the highest level of red blood cells in the TPO-
plus-5-AED-treated group would consequently result in the lowest
levels of erythropoietin. This is consistent with the observation
that TPO plus 5-AED combination treatment resulted in an
increased number of BFU-E in comparison to treatment with
5-AED alone (P<.05) but with a decreased number of CFU-E,
which for their maturation strongly depend on the presence of
erythropoietin. TPO affects progenitor cell viability by preventing
apoptosis and can affect erythropoiesis by binding to the TPO
receptor c-mpl or through activation of the erythropoietin receptor.
The additive effect observed on BFU-E of 5-AED and TPO may
be the result of TPO-related stimulation of increased numbers of
viable erythroid progenitor cells. Combined treatment with
5-AED and TPO resulted in an increase of 20.1-fold of CFU-S-12
in comparison to radiation controls (P<1010), and a 3.1 and
Fig. 5. Secondary marrow repopulating ability after fraction-
ated TBI Marrow repopulating ability (MRA): GM-CFU per
femur (A) or spleen (B), ranked in ascending order on day 13 of
recipients of the cellular content of 1 femur at 24 h after the last
radiation fraction of mice treated with 40 mg/kg 5-AED IM 2 h
after each fraction of 2 Gy TBI (black bars, survival 10/10) in
comparison with recipients receiving control BM derived from
mice that did not receive treatment (white bars, survival 8/10) and
with recipients transplanted with 105 BM cells from normal,
unirradiated and untreated donors (striped bars, survival 10/10). A
total of 10 mice per group were injected with BM cells. Bars
represent the data from individual mice.
Fig. 6. Colony forming unit-spleen after fractionated TBI
Colony forming unit-spleen (CFU-S): 8 Gy irradiated recipient
mice were injected with BM cells from donor mice subjected to
3  2 Gy, followed by treatment with placebo, 40 mg/kg/d 5-AED
(AED) IM or 9 mg/kg TPO (T) IP at 2 h after each fraction, 400
mg/kg Peg-G-CSF (G) IP at 2 h after the first fraction only, or
combinations. Recipients were killed at 12 days after trans-
plantation and spleen colonies were enumerated. Data are depicted
as average plus SD of 1-3 separate experiments, nZ10 mice per
group per experiment. Significantly different from time matched
placebo controls: *P<105; **P<1010; from TPO alone:
#P<107 and from 5-AED alone: & P<1010.
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(P<1010), respectively. Such a dramatic response was not
observed after treatment with Peg-G-CSF alone or in the presence
of 5-AED. This confirms that the observed effects of Peg-G-CSF
cannot be attributed to increased survival of short-term repopu-
lating stem cells, but rather by amplified expansion of surviving
progenitors (19, 20), whereas 5-AED selectively enhances the
properties of TPO to protect transplantable short-term repopulat-
ing immature hematopoietic stem cells.
The pattern through which 5-AED promotes radiation miti-
gation is distinct from that of TPO, as TPO promoted CFU-S but
at the transient expense of MRA (4), whereas 5-AED promotes
CFU-S to a similar extent as TPO but simultaneously promotes
recovery of MRA. Cytokine array tests showed an increase of
circulating G-CSF and IL-6 but not TPO after 5-AED treatment
in vivo (14) and in vitro (15). These data support the hypothesis
that the observed synergistic effect of 5-AED in presence of TPO
is the result of activation of an alternative pathway, whereas the
lack of additive effect in presence of G-CSF strongly suggests the
use of a common shared pathway. Thus, in addition to TPO other
hematopoietic growth factors may also act in concert with 5-AED,promoting the radiation mitigation effect on HSCs. Detailed
mechanistic studies are warranted to optimize the radiation miti-
gation effects of 5-AED alone or in concert with hematopoietic
growth factors.
Conclusions
In conclusion, 5-AED stimulates multilineage hematopoiesis and
increases BM and spleen cellularity following TBI. This effect is
mediated by increased survival and/or reconstitution of immature
repopulating cells in a pattern distinct from that of TPO. 5-AED
strongly synergizes with TPO at the level of immature progenitor
cells, thus revealing a novel mechanism of BM protection. In view
of these results, the steroid 5-AED should be classified as
a powerful radiation mitigation agent, the effects of which occur
primarily at the level of immature stem cell subsets.
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